CD19-dBiTE

N/A

Report date: 2026/03/19 16:59:33

Base Information

Drug NameCD19-dBiTE

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsT cell surface glycoprotein CD3 modulators

TargetsT cell surface glycoprotein CD3B-lymphocyte antigen CD19

Therapy Area/IndicationsLymphoma, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesInovio Pharmaceuticals Inc

China Registration ClassN/A

Develop Information

Active CompaniesInovio Pharmaceuticals Inc

Inactive CompaniesN/A

Active IndicationsLymphoma, B-Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A